OXT and schizophrenia: Driven by the convergent findings in preclinical studies and the investigation of oxytocin dysregulation in patients with schizophrenia, burgeoning evidence from the double-blind randomized controlled trials demonstrates encouraging results using intranasal oxytocin as an augmentation to antipsychotics in ameliorating both the positive and negative symptoms of schizophrenia.